share_log

Redhill Biopharma | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Redhill Biopharma | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Redhill Biopharma | 6-K：外国发行人报告
SEC announcement ·  03/21 16:08
Moomoo AI 已提取核心信息
Redhill Biopharma Ltd., a foreign private issuer, has successfully passed a resolution to increase its authorized share capital at the Extraordinary General Meeting of Shareholders held on March 21, 2024. The resolution was approved by the company's shareholders, as reported in the Form 6-K filed with the United States Securities and Exchange Commission. This corporate action is now incorporated by reference into the company's various Registration Statements on Forms S-8 and F-3, which have been previously filed with the SEC on specified dates ranging from May 2, 2013, to October 13, 2023. The Form 6-K serves as a legal document that ensures the company adheres to the SEC regulations by providing timely updates on significant corporate events.
Redhill Biopharma Ltd., a foreign private issuer, has successfully passed a resolution to increase its authorized share capital at the Extraordinary General Meeting of Shareholders held on March 21, 2024. The resolution was approved by the company's shareholders, as reported in the Form 6-K filed with the United States Securities and Exchange Commission. This corporate action is now incorporated by reference into the company's various Registration Statements on Forms S-8 and F-3, which have been previously filed with the SEC on specified dates ranging from May 2, 2013, to October 13, 2023. The Form 6-K serves as a legal document that ensures the company adheres to the SEC regulations by providing timely updates on significant corporate events.
外国私人发行人红山生物制药有限公司在2024年3月21日举行的特别股东大会上成功通过了一项增加其法定股本的决议。如向美国证券交易委员会提交的6-K表格所述，该决议已获得公司股东的批准。该公司诉讼现已通过引用方式纳入公司关于S-8和F-3表格的各种注册声明，这些声明先前已在2013年5月2日至2023年10月13日的指定日期向美国证券交易委员会提交。6-K表格是一份法律文件，通过及时提供重大公司活动的最新信息，确保公司遵守美国证券交易委员会的法规。
外国私人发行人红山生物制药有限公司在2024年3月21日举行的特别股东大会上成功通过了一项增加其法定股本的决议。如向美国证券交易委员会提交的6-K表格所述，该决议已获得公司股东的批准。该公司诉讼现已通过引用方式纳入公司关于S-8和F-3表格的各种注册声明，这些声明先前已在2013年5月2日至2023年10月13日的指定日期向美国证券交易委员会提交。6-K表格是一份法律文件，通过及时提供重大公司活动的最新信息，确保公司遵守美国证券交易委员会的法规。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息